TsungYuan Shen specializes in the fields of biomedical and food technology law, intellectual property protection, unfair competition, construction/BOT, and dispute resolution. His professional background spans biotechnology, law, and economics.
Mr. Shen has represented many biotech-related companies in the fields of pharmaceuticals, medical instruments, chemicals, health food and GMO; and governmental research organizations in IPR matters and legal matters. He has also advised high-tech companies in the fields of electronics, optoelectronics, communications, precision industry, and multinational construction companies on matters of IPR, high-tech laws and public construction disputes.
Clients served by Mr. Shen include Pfizer, Merck Sharp & Dohme, DuPont, TSMC, AU Optronics, Qualcomm, Molex, Lockheed Martin, and other leading companies or organizations.
Mr. Shen has also utilized his background in economics in cases involving the management or licensing of IP portfolios. In addition, he has acted on behalf of companies during governmental investigations of unfair competition and in administrative lawsuits with outstanding results.
- Stanford Law School: International Professional Summer Program: Understanding U.S. Intellectual Property Law (2016)
- National Taiwan University Law School: LL.B (2008)
- National Taiwan University Life Science School: B.S. (2008)
- National Taiwan University: Minor in Economics (2008)
- WIPO: General Course in Intellectual Property (2006)
Biomedical & Food Tech Law，Intellectual Property Protection，High-Tech Law，Unfair Competition，Construction & BOT，Dispute Resolution，
Vice Chairman, Intellectual Properties & Innovation Technologies Committee of Taipei Bar Association (2017-present)
Chairman, Biotechnology Laws Committee of Taipei Bar Association (2014-2017)
Commissioner, ICC Committee of Taipei Bar Association (2018-present)
Commissioner, Environmental Laws Committee of Taipei Bar Association (2011-present)
Commissioner, Environmental Laws Committee of Taiwan Bar Association (2014-present)
Commissioner, Medical & Health Laws Committee of Taipei Bar Association (2011-present)
Member, Taiwan Society of Health Law (2012-present)
Senior Attorney, Formosa Transnational Attorneys-at-Law (2010-2014)
Member, Taiwan Bar (Admitted 2010)
Patent Engineer, Bio-Biz-Law Inc. (2005-2007)
|2020||Is Commercial Success a Factor Considered in Determining the Non-obviousness of a Patent?
LEE & LI Bulletin - July 2020
|2020||The Supreme Administrative Court’s Elaboration on the Claim Construction
LEE & LI Bulletin - May 2020
|2020||TIPO releases patent information for COVID-19 clinical trial drugs
ILO IP Newsletter (20200427)
|2020||The Taiwan Intellectual Property Office (TIPO) Releases Taiwanese Patent Information for Novel Coronavirus Clinical Trial Drugs
LEE & LI Bulletin - March 2020
|2019||An Intellectual Property Court's Elaboration on the Non-compete Clause and Non-Disclosure Agreement
LEE & LI Bulletin - May 2019
|2019||Supreme Administrative Court interprets teaching away requirements
ILO IP Newsletter (20190415)
|2019||The Taiwan Supreme Administrative Court’s Interpretation on "Teach Away"
LEE & LI Bulletin - March 2019
|2018||A Study of Concurrence of Patent Infringements and Unjust Enrichment
LEE & LI Bulletin - November 2018
|2018||The Validity of a Patent License Contract after the Claims of the Licensed Patents are Found to be Partially Invalid
LEE & LI Bulletin - September 2018